Creo Medical Group (LON:CREO) Hits New 1-Year Low – What’s Next?

Creo Medical Group PLC (LON:CREO) hit a new 52-week low during trading on Friday. The company traded as low as GBX 9.50 and last traded at GBX 9.67, with a volume of 2207440 shares changing hands. The stock had previously closed at GBX 9.80.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 target price on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Stock Performance

The company has a market cap of £46.96 million, a PE ratio of 9.67 and a beta of 1.56. The stock has a 50 day simple moving average of GBX 12.62 and a two-hundred day simple moving average of GBX 12.82. The company has a debt-to-equity ratio of 8.09, a current ratio of 2.79 and a quick ratio of 2.19.

Creo Medical Group (LON:CREO) last announced its earnings results on Wednesday, September 30th. The company reported GBX (2) EPS for the quarter. Creo Medical Group had a negative net margin of 268.57% and a negative return on equity of 38.29%. Equities analysts predict that Creo Medical Group PLC will post -10.0800005 EPS for the current year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.